EGFR and lung cancer: Targeted delivery of EV‐encapsulated PTX at a low dose (10‐20 times lower than the clinical‐equivalent dose) significantly enhanced the drug efficacy in suppressing tumour growth in an EGFR‐positive lung cancer xenografted mouse model.